

Michael Ong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2560975/publications.pdf>

Version: 2024-02-01

64
papers

2,079
citations

361413
20
h-index

243625
44
g-index

65
all docs

65
docs citations

65
times ranked

4141
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolving real-world patterns of practice in metastatic castration-sensitive prostate cancer (mCSPC): The genitourinary research consortium (GURC) national multicenter cohort study.. Journal of Clinical Oncology, 2022, 40, 86-86.	1.6	2
2	Real-world associations between bone-targeted agents and palliative bone radiotherapy in prostate cancer decedents: A province-wide population study.. Journal of Clinical Oncology, 2022, 40, e17043-e17043.	1.6	0
3	OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 460-472.	7.0	48
4	A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. European Journal of Cancer, 2021, 142, 132-140.	2.8	42
5	UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castrate-sensitive prostate cancer.. Journal of Clinical Oncology, 2021, 39, 117-117.	1.6	0
6	Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review. Cancers, 2021, 13, 1905.	3.7	7
7	Canadian consensus forum of key controversial areas in the management of advanced prostate cancer. Canadian Urological Association Journal, 2021, 15, 353-358.	0.6	2
8	The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review. Oncologist, 2021, 26, e1381-e1394.	3.7	8
9	Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice. Journal of Urology, 2021, 206, 240-251.	0.4	7
10	Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. Journal of Bone Oncology, 2021, 30, 100388.	2.4	6
11	A Contemporary Report of Clinical Outcomes in Patients with Melanoma Brain Metastases. Current Oncology, 2021, 28, 428-439.	2.2	3
12	Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108. Cancer, 2020, 126, 432-443.	4.1	13
13	Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. European Urology Oncology, 2020, 3, 176-182.	5.4	19
14	Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. Canadian Urological Association Journal, 2020, 15, E90-E96.	0.6	3
15	Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence. Annals of Surgical Oncology, 2020, 27, 3683-3691.	1.5	13
16	Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection. Canadian Urological Association Journal, 2020, 14, E373-E382.	0.6	8
17	Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. British Journal of Cancer, 2020, 122, 1324-1332.	6.4	23
18	Rechallenge Strategy in Cancer Therapy. Oncology, 2020, 98, 669-679.	1.9	9

#	ARTICLE	IF	CITATIONS
19	Evolution in upfront treatment strategies for metastatic RCC. Nature Reviews Urology, 2020, 17, 73-74.	3.8	9
20	Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 863-868.	2.3	4
21	Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 5551-5551.	1.6	7
22	Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study.. Journal of Clinical Oncology, 2020, 38, 5035-5035.	1.6	0
23	Real-world management of advanced prostate cancer: A Canadian comparison of academic specialists and community-based prostate cancer physicians.. Journal of Clinical Oncology, 2020, 38, 29-29.	1.6	0
24	An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2019, 25, 6709-6720.	7.0	32
25	A A Canadian consensus forum on the management of patients with advanced prostate cancer. Canadian Urological Association Journal, 2019, 14, E137-E149.	0.6	15
26	The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity. Medical Oncology, 2019, 36, 18.	2.5	6
27	Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2019, 14, E115-E125.	0.6	3
28	A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 11501-11501.	1.6	10
29	Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or enzalutamide (ENZ) in poor prognosis metastatic CRPC.. Journal of Clinical Oncology, 2019, 37, 5003-5003.	1.6	2
30	Population kinetics of progression free survival (PFS).. Journal of Clinical Oncology, 2019, 37, e18251-e18251.	1.6	1
31	Clinical outcomes in patients with melanoma brain metastases at a tertiary cancer center.. Journal of Clinical Oncology, 2019, 37, e13586-e13586.	1.6	1
32	Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer.. Journal of Clinical Oncology, 2019, 37, e16501-e16501.	1.6	0
33	Immune Checkpoint Inhibitors: Game Changing Cancer Therapy With a Cardiac Cost. What Are the Mechanisms and Unresolved Questions in Cardiotoxicity?. Canadian Journal of Cardiology, 2018, 34, 970-971.	1.7	1
34	Influence of aggressive-variant prostate cancer (AVPC) features on outcome of metastatic hormone-sensitive prostate cancer (mHSPC) treated by chemohormonal therapy (CHT).. Journal of Clinical Oncology, 2018, 36, 193-193.	1.6	2
35	Impact of surveillance-detected metastatic recurrence on treatment outcomes of high-risk melanoma.. Journal of Clinical Oncology, 2018, 36, e21612-e21612.	1.6	1
36	Patient-reported outcomes (PROs) in patients with urothelial carcinoma (UC) treated with durvalumab (second-line or above) in phase 1/2 dose-escalation study 1108.. Journal of Clinical Oncology, 2018, 36, 4532-4532.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Early changes in PSA and association with outcomes in mCRPC patients.. Journal of Clinical Oncology, 2018, 36, 5063-5063.	1.6	0
38	The timing of docetaxel initiation in metastatic castrate sensitive prostate cancer and the rate of chemotherapy induced toxicity.. Journal of Clinical Oncology, 2018, 36, e17005-e17005.	1.6	0
39	Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma. JAMA Oncology, 2017, 3, e172411.	7.1	750
40	A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 1-6.	1.9	13
41	Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC).. Journal of Clinical Oncology, 2017, 35, 4525-4525.	1.6	30
42	Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2017, 35, 286-286.	1.6	45
43	Evaluating the impact of bone-targeted agents in the era of novel androgen targeted therapy for metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2017, 35, e16500-e16500.	1.6	0
44	Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review. Supportive Care in Cancer, 2016, 24, 3633-3650.	2.2	33
45	Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. , 2016, 4, 64.		75
46	Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review. Supportive Care in Cancer, 2016, 24, 1583-1594.	2.2	29
47	A multi-centre study to investigate the natural history of taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast or prostate cancer.. Journal of Clinical Oncology, 2016, 34, e21594-e21594.	1.6	0
48	AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer — results of two parallel first-in-human phase I studies. Investigational New Drugs, 2015, 33, 679-690.	2.6	43
49	Antitumor Activity in <i>RAS</i>-Driven Tumors by Blocking AKT and MEK. Clinical Cancer Research, 2015, 21, 739-748.	7.0	121
50	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clinical Cancer Research, 2015, 21, 4586-4596.	7.0	171
51	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clinical Cancer Research, 2015, 21, 3412-3419.	7.0	101
52	Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. British Journal of Cancer, 2014, 111, 828-836.	6.4	34
53	Long-term benefits versus side-effects from bone-targeted therapies for cancer patients. Current Opinion in Supportive and Palliative Care, 2014, 8, 420-428.	1.3	10
54	Novel drugs targeting the androgen receptor pathway in prostate cancer. Cancer and Metastasis Reviews, 2014, 33, 567-579.	5.9	29

#	ARTICLE	IF	CITATIONS
55	Phase I dose escalation study of 3-weekly BI 836845, a fully human, affinity optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, 2622-2622.	1.6	4
56	Appraising iniparib, the PARP inhibitor that never was—what must we learn?. Nature Reviews Clinical Oncology, 2013, 10, 688-696.	27.6	81
57	A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2013, 31, 4511-4511.	1.6	7
58	Using a knowledge translation framework to implement asthma clinical practice guidelines in primary care. International Journal for Quality in Health Care, 2012, 24, 538-546.	1.8	34
59	Choroidal lymphoma with orbital and optic nerve extension: case and review of literature. Canadian Journal of Ophthalmology, 2012, 47, 79-81.	0.7	22
60	An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer. Current Respiratory Medicine Reviews, 2011, 7, 354-363.	0.2	0
61	Recent advances in second-line treatment of castration-resistant prostate cancer. Current Opinion in Supportive and Palliative Care, 2011, 5, 199-205.	1.3	3
62	Pharmacological Risk Factors for Amphotericin B Nephrotoxicity in Children. Journal of Clinical Pharmacology, 2007, 47, 1049-1054.	2.0	13
63	Unscheduled Return Visits to the Pediatric Emergency Department-One-Year Experience. Pediatric Emergency Care, 2006, 22, 545-549.	0.9	98
64	Octreotide in Bronchobiliary Fistula Management. Annals of Thoracic Surgery, 2004, 78, 1512-1513.	1.3	24